<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE trials [
<!ELEMENT trials (trial+)>

<!ELEMENT trial (main,contacts,countries,criteria,health_condition_code,health_condition_keyword,intervention_code,
          intervention_keyword,primary_outcome,secondary_outcome,secondary_sponsor,secondary_ids,source_support,ethics_reviews)>

<!ELEMENT main (trial_id,utrn?,reg_name,date_registration,primary_sponsor,public_title,acronym?,scientific_title,scientific_acronym?,
          date_enrolment,type_enrolment,target_size,recruitment_status,url?,study_type,study_design,phase,hc_freetext?,i_freetext?,results_actual_enrolment,results_date_completed,results_url_link,results_summary,           results_date_posted,results_date_first_publication,results_baseline_char,results_participant_flow,results_adverse_events,results_outcome_measures,results_url_protocol,results_IPD_plan, results_IPD_description)>
<!ELEMENT trial_id (#PCDATA)>
<!ELEMENT utrn (#PCDATA)>
<!ELEMENT reg_name (#PCDATA)>
<!ELEMENT date_registration (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT primary_sponsor (#PCDATA)>
<!ELEMENT public_title (#PCDATA)>
<!ELEMENT acronym (#PCDATA)>
<!ELEMENT scientific_title (#PCDATA)>
<!ELEMENT scientific_acronym (#PCDATA)>
<!ELEMENT date_enrolment (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT type_enrolment (#PCDATA)>
<!ELEMENT target_size (#PCDATA)>
<!ELEMENT recruitment_status (#PCDATA)><!-- Pending,Recruiting,Suspended,Complete,Other -->
<!ELEMENT url (#PCDATA)>
<!ELEMENT study_type (#PCDATA)><!-- interventional,observational -->
<!ELEMENT study_design (#PCDATA)>
<!ELEMENT phase (#PCDATA)>
<!ELEMENT hc_freetext (#PCDATA)>
<!ELEMENT i_freetext (#PCDATA)>
<!ELEMENT results_actual_enrolment (#PCDATA)>
<!ELEMENT results_date_completed (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_url_link (#PCDATA)>
<!ELEMENT results_summary (#PCDATA)>
<!ELEMENT results_date_posted (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_date_first_publication (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_baseline_char (#PCDATA)>
<!ELEMENT results_participant_flow (#PCDATA)>
<!ELEMENT results_adverse_events (#PCDATA)>
<!ELEMENT results_outcome_measures (#PCDATA)>
<!ELEMENT results_url_protocol (#PCDATA)>
<!ELEMENT results_IPD_plan (#PCDATA)>
<!ELEMENT results_IPD_description (#PCDATA)>


<!ELEMENT contacts (contact+)>
<!ELEMENT contact (type,firstname,middlename,lastname,address,city,country1,zip,telephone,email,affiliation)>
<!ELEMENT type (#PCDATA)><!-- Public,Scientific -->
<!ELEMENT firstname (#PCDATA)>
<!ELEMENT middlename (#PCDATA)>
<!ELEMENT lastname (#PCDATA)>
<!ELEMENT address (#PCDATA)>
<!ELEMENT city (#PCDATA)>
<!ELEMENT country1 (#PCDATA)>
<!ELEMENT zip (#PCDATA)>
<!ELEMENT telephone (#PCDATA)>
<!ELEMENT email (#PCDATA)>
<!ELEMENT affiliation (#PCDATA)>

<!ELEMENT countries (country2+)>
<!ELEMENT country2 (#PCDATA)>

<!ELEMENT criteria (inclusion_criteria,agemin,agemax,gender,exclusion_criteria)>
<!ELEMENT inclusion_criteria (#PCDATA)>
<!ELEMENT agemin (#PCDATA)>
<!ELEMENT agemax (#PCDATA)>
<!ELEMENT gender (#PCDATA)>
<!ELEMENT exclusion_criteria (#PCDATA)>

<!ELEMENT health_condition_code (hc_code+)>
<!ELEMENT hc_code (#PCDATA)>

<!ELEMENT health_condition_keyword (hc_keyword+)>
<!ELEMENT hc_keyword (#PCDATA)>

<!ELEMENT intervention_code (i_code+)>
<!ELEMENT i_code (#PCDATA)>

<!ELEMENT intervention_keyword (i_keyword+)>
<!ELEMENT i_keyword (#PCDATA)>

<!ELEMENT primary_outcome (prim_outcome+)>
<!ELEMENT prim_outcome (#PCDATA)>

<!ELEMENT secondary_outcome (sec_outcome+)>
<!ELEMENT sec_outcome (#PCDATA)>

<!ELEMENT secondary_sponsor (sponsor_name+)>
<!ELEMENT sponsor_name (#PCDATA)>

<!ELEMENT secondary_ids (secondary_id+)>
<!ELEMENT secondary_id (sec_id,issuing_authority)>
<!ELEMENT sec_id (#PCDATA)>
<!ELEMENT issuing_authority (#PCDATA)>

<!ELEMENT source_support (source_name+)>
<!ELEMENT source_name (#PCDATA)>

<!ELEMENT ethics_reviews (ethics_review+)>
<!ELEMENT ethics_review (status,approval_date,contact_name,contact_address,contact_phone,contact_email)>
<!ELEMENT status (#PCDATA)><!-- Not approved,Approved,NA -->
<!ELEMENT approval_date (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT contact_name (#PCDATA)>
<!ELEMENT contact_address (#PCDATA)>
<!ELEMENT contact_phone (#PCDATA)>
<!ELEMENT contact_email (#PCDATA)>
]>
<trials>
  <trial>
    <main>
      <trial_id>IRCT2013060713567N2</trial_id>
      <utrn></utrn>
      <reg_name>IRCT</reg_name>
      <date_registration>2013-10-03</date_registration>
      <primary_sponsor>vice-chancellor for research Tehran University of Medical Sciences</primary_sponsor>
      <public_title>Comparing different artificial tear drops on post operative ocular discomfort after photorefractive keratectomy.</public_title>
      <acronym></acronym>
      <scientific_title>Comparative study of two artificial tear drops, hyaluronic acid containing artificial tears versus hyaluronic free artificial tears in controlling post surgical eye discomfort following photorefractive keratectomy .</scientific_title>
      <scientific_acronym></scientific_acronym>
      <date_enrolment>2013-10-23</date_enrolment>
      <type_enrolment>anticipated</type_enrolment>
      <target_size>118</target_size>
      <recruitment_status>Complete</recruitment_status>
      <url>https://irct.ir/trial/13387</url>
      <study_type>interventional</study_type>
      <study_design>Randomization: Randomized, Blinding: Triple blinded, Placebo: Not used, Assignment: Parallel, Purpose: Supportive.</study_design>
      <phase>N/A</phase>
      <hc_freetext>hyperopia, myopia.</hc_freetext>
      <i_freetext>Intervention 1: For first experimental group, Mitomycin C is used prior to operation, contact lens bandages are used right after surgery and three different eye drops are administered for the following week:&#13;
Chloramphenicol 0.1% every six hours for four days.&#13;
Betamethasone 0.1% every six hours for two weeks and then tapered over two weeks.&#13;
Diclofenac 0.1%   every six hours for a day.&#13;
Additionally for all patients fluorometholone 0.1% is started on the second month, administered every six hours and then tapered off over two months.&#13;
For this group Artelac advanced is used as the artificial tear. This is a hyaluronic acid containing artificial tear used every four hours for the first week and then tapered off over three months. Intervention 2: For the second experimental group, Mitomycin C is used prior to operation, contact lens bandages are used right after surgery and three different eye drops are administered for the following week:&#13;
Chloramphenicol 0.1% every six hours for four days.&#13;
Betamethasone 0.1% every six hours for two weeks and then tapered over two weeks.&#13;
Diclofenac 0.1%   every six hours for a day.&#13;
Additionally for all patients fluorometholone 0.1% is started on the second month, administered every six hours and then tapered off over two months.&#13;
This group will receive preservative free Artelac which is an artificial tear that does not contain hyaluronic acid and is used every four hours in the first week and then tapered off over three months. Intervention 3: For the control group, Mitomycin C is used prior to operation, contact lens bandages are used right after surgery and three different eye drops are administered for the following week:&#13;
Chloramphenicol 0.1% every six hours for four days.&#13;
Betamethasone 0.1% every six hours for two weeks and then tapered over two weeks.&#13;
Diclofenac 0.1%   every six hours for a day.&#13;
Additionally for all patients fluorometholone 0.1% is started on the second month, administered every six hours and then tapered off over two months.&#13;
Artificial tears are not administered to this group of patients.</i_freetext>
      <results_actual_enrolment></results_actual_enrolment>
      <results_date_completed></results_date_completed>
      <results_url_link></results_url_link>
      <results_summary></results_summary>
      <results_date_posted></results_date_posted>
      <results_date_first_publication></results_date_first_publication>
      <results_baseline_char></results_baseline_char>
      <results_participant_flow></results_participant_flow>
      <results_adverse_events></results_adverse_events>
      <results_outcome_measures></results_outcome_measures>
      <results_url_protocol></results_url_protocol>
      <results_IPD_plan></results_IPD_plan>
      <results_IPD_description></results_IPD_description>
    </main>
    <contacts>
      <contact>
        <type>public</type>
        <firstname>Mehrdad Mohammadpour</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Eye Research Center, Farabi hospital, Qazvin Sq.</address>
        <city>Tehran</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip></zip>
        <telephone>+98 21 5542 1006</telephone>
        <email>mohammadpour_m@sina.tums.ac.ir</email>
        <affiliation>Tehran University of Medical Sciences</affiliation>
      </contact>
      <contact>
        <type>scientific</type>
        <firstname>Mehrdad Mohammadpour</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Farabi eye hospital, Qazvin Sq.</address>
        <city>Tehran</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip></zip>
        <telephone>+98 21 5542 1006</telephone>
        <email>mahammadpour@yahoo.com</email>
        <affiliation>Eye Research Center, Farabi  hospital</affiliation>
      </contact>
    </contacts>
    <countries>
      <country2>Iran (Islamic Republic of)</country2>
    </countries>
    <criteria>
      <inclusion_criteria>Inclusion criteria: Over 18 year of age, Less than 0.5 Diopter change in visual acuity in the previous year, Myopia -1.0 to -6.0, Astigmatism 0.75 to 3.0, Hyperopia +1.0to +4.0, Corneal stroma more than 450 micron, Pupil size less than 6mm. Exclusion criteria: Keratoconus, Herpetic keratitis, Corneal dystrophy, Corneal degeneration, Cataract, Glaucoma, Dry eye, Lag ophthalmos, Uveitis, Blepharitis, diabetes, Pregnancy, Breast feeding, Auto immune disease, Immunodeficiency, History of keloid formation.</inclusion_criteria>
      <agemin>18 years</agemin>
      <agemax>60 years</agemax>
      <gender>Both</gender>
      <exclusion_criteria></exclusion_criteria>
    </criteria>
    <health_condition_code>
      <hc_code>H54.3</hc_code>
    </health_condition_code>
    <health_condition_keyword>
      <hc_keyword>mild or no visual impairment, binocular</hc_keyword>
    </health_condition_keyword>
    <intervention_code>
      <i_code>Treatment - Drugs</i_code>
      <i_code>Treatment - Drugs</i_code>
      <i_code>Treatment - Drugs</i_code>
    </intervention_code>
    <intervention_keyword>
      <i_keyword>For first experimental group, Mitomycin C is used prior to operation, contact lens bandages are used right after surgery and three different eye drops are administered for the following week:&#13;
Chloramphenicol 0.1% every six hours for four days.&#13;
Betamethasone 0.1% every six hours for two weeks and then tapered over two weeks.&#13;
Diclofenac 0.1%   every six hours for a day.&#13;
Additionally for all patients fluorometholone 0.1% is started on the second month, administered every six hours and then tapered off over two months.&#13;
For this group Artelac advanced is used as the artificial tear. This is a hyaluronic acid containing artificial tear used every four hours for the first week and then tapered off over three months.</i_keyword>
      <i_keyword>For the second experimental group, Mitomycin C is used prior to operation, contact lens bandages are used right after surgery and three different eye drops are administered for the following week:&#13;
Chloramphenicol 0.1% every six hours for four days.&#13;
Betamethasone 0.1% every six hours for two weeks and then tapered over two weeks.&#13;
Diclofenac 0.1%   every six hours for a day.&#13;
Additionally for all patients fluorometholone 0.1% is started on the second month, administered every six hours and then tapered off over two months.&#13;
This group will receive preservative free Artelac which is an artificial tear that does not contain hyaluronic acid and is used every four hours in the first week and then tapered off over three months.</i_keyword>
      <i_keyword>For the control group, Mitomycin C is used prior to operation, contact lens bandages are used right after surgery and three different eye drops are administered for the following week:&#13;
Chloramphenicol 0.1% every six hours for four days.&#13;
Betamethasone 0.1% every six hours for two weeks and then tapered over two weeks.&#13;
Diclofenac 0.1%   every six hours for a day.&#13;
Additionally for all patients fluorometholone 0.1% is started on the second month, administered every six hours and then tapered off over two months.&#13;
Artificial tears are not administered to this group of patients.</i_keyword>
    </intervention_keyword>
    <primary_outcome>
      <prim_outcome>Ocular discomfort (including pain, epiphora, foreign body sensation, blurred vision and photophobia). Timepoint: First and fourth day post operation. Method of measurement: Questionnaire.</prim_outcome>
      <prim_outcome>Visual acuity. Timepoint: On the first, third and sixth month after surgery. Method of measurement: Snelen  chart.</prim_outcome>
      <prim_outcome>Aberrometry. Timepoint: Sixth months after surgery. Method of measurement: Aberrometer.</prim_outcome>
      <prim_outcome>Corneal haze. Timepoint: On the first, third and sixth month after surgery. Method of measurement: Slit lamp.</prim_outcome>
    </primary_outcome>
    <secondary_outcome>
      <sec_outcome></sec_outcome>
    </secondary_outcome>
    <secondary_sponsor>
      <sponsor_name></sponsor_name>
    </secondary_sponsor>
    <secondary_ids>
      <secondary_id>
        <sec_id></sec_id>
        <issuing_authority></issuing_authority>
      </secondary_id>
    </secondary_ids>
    <source_support>
      <source_name>vice-chancellor for research Tehran University of Medical Sciences</source_name>
    </source_support>
    <ethics_reviews>
      <ethics_review>
        <status>Approved</status>
        <approval_date>2012-06-10</approval_date>
        <contact_name>Research Ethics Committee at Tehran university of medical science</contact_name>
        <contact_address>Qods Ave., Keshavarz Ave., Enghelab Ave., Tehran Tehran  Iran (Islamic Republic of)</contact_address>
        <contact_phone></contact_phone>
        <contact_email></contact_email>
      </ethics_review>
    </ethics_reviews>
  </trial>
</trials>
